Ozen, FurkanTekin, SuatKoran, KenanSandal, SuleymanGorgulu, Ahmet Orhan2024-08-042024-08-0420160922-61681568-5675https://doi.org/10.1007/s11164-016-2562-3https://hdl.handle.net/11616/97309A series of 2-(2,3,4-trimethoxyphenyl)-1-(substituted-phenyl)acrylonitrile (2-9) were designed and synthesized to develop new cancer drugs. The structures of synthesized compounds 2-9 were described by using melting point, mass (MALDI-TOF-MS), FT-IR, elemental analysis, H-1, C-13, C-13-APT and 2D NMR spectroscopy. The in vitro anticancer activities of 2-9 against human breast cancer (MCF-7), human prostate cancer (PC-3) and human ovarian cancer cells (A2780) were investigated by [3-(4,5-dimethylthiazol)-2-yl]-2,5-diphenyl-2H-tetrazolium bromide] (MTT) assay method. Additionally, the LogIC(50) values of these compounds on A2780, MCF-7 and PC-3 cell lines were calculated by using inhibition % values by the GraphPad Prism 6 program on a computer. The results indicated that these compounds have high anticancer activity against MCF-7, PC-3 and A2780 cell lines (especially A2780 cell lines, p < 0.05).eninfo:eu-repo/semantics/closedAccessPhenylacrylonitrile derivativesHuman ovarian cancer cellMCF-7Anticancer evaluationPC-3Article42127793780510.1007/s11164-016-2562-32-s2.0-84966335572Q2WOS:000388141100002Q3